Abstract 435TiP
Background
Treatment with PD-L1 or PD-1 targeting antibodies is a cornerstone in cancer therapy, but not all patients benefit from these drugs. For most indications, the current reference biomarker is PD-L1 expression in a tumor biopsy, but this method has several disadvantages. Molecular imaging, such as PET/CT using receptor-specific radiotracers, offers non-invasive, real-time visualization of treatment targets. Previous trials have explored a few PD-L1/PD-1 radiotracers but lacked a systematic approach focused on a single tumor type and standardized clinical management.
Trial design
The MIMIR-trial (EU CT 2022-500808-21-00, NCT05742269) involves newly diagnosed mTNBC patients planned for first-line systemic treatment. Participants undergo a PD-L1 PET/CT scan with [89Zr]Zr-atezolizumab followed by a biopsy, with results guiding subsequent treatment with chemotherapy (carboplatin and nab-paclitaxel), combined with atezolizumab based on PD-L1 status as determined by IHC and/or PET. Treatment effectiveness is assessed bi-monthly, and therapy is continued until disease progression or unmanageable toxicity. The primary aim is to determine the statistical concordance (Cohen’s kappa coefficient) between PD-L1 status by PET and IHC. To target a kappa of 0.80 with a precision of +/- 0.15, 64 patients are required in this study. Secondary objectives include evaluating the predictive value of PD-L1 PET for treatment response and development of immunotherapy-mediated toxicity. Tissue, feces, and blood samples are collected for further translational analysis. The trial is ongoing at Karolinska University Hospital in Stockholm, Sweden, with three patients enrolled so far. An additional cohort of patients with non small cell lung cancer will be opened during Q3-4 2024.
Clinical trial identification
EU CT 2022-500808-21-00, NCT05742269.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University hospital, Region Stockholm, Sweden.
Funding
Roche Sweden AB.
Disclosure
J. Bergh: Non-Financial Interests, Personal, Advisory Board: stratipath. All other authors have declared no conflicts of interest.
Resources from the same session
383P - Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer
Presenter: Andreas Varkaris
Session: Poster session 15
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
388P - Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
Presenter: jin xiang
Session: Poster session 15
390P - SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Presenter: Maria Cona
Session: Poster session 15
391P - Real-world activity of sacituzumab govitecan for metastatic breast cancer
Presenter: Stefania Morganti
Session: Poster session 15
392P - Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Adam Brufsky
Session: Poster session 15